The study will examine the safety and efficacy of Prodisc C in cervical disc injury, according to a December news release.
The trial aims to demonstrate that Prodisc C SK and Prodisc C Vivo are at least as safe and effective as Mobi-C — a similar cervical disc prosthesis on the market — to treat symptomatic cervical disc disease at two contiguous levels from C3 to C7.
Masson Spine Institute is now enrolling patients in the clinical trial.
More articles on practice management:
How CMS’ changes will affect spine surgeons in 2021 — Prior authorization, fee cuts & more
Former orthopedic practice owner gets 5 years in prison for illegally prescribing opioids
Surgeons’ brand exceeds patient outcomes — How you should build your practice’s brand
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
